ArticleJournal of Alzheimer's disease : JAD2012
Elevated plasma MCP-1 concentration following traumatic brain injury as a potential "predisposition" factor associated with an increased risk for subsequent development of Alzheimer's disease.
Article in Journal of Alzheimer's disease : JAD, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Association of traumatic brain injury with subsequent neurological and psychiatric disease: a meta-analysis.Journal of neurosurgery · 2016Pooled it
- Early measurement of interleukin-10 predicts the absence of CT scan lesions in mild traumatic brain injury.PloS one · 2018Trial
- Correlation of Routine Admission Inflammatory Biomarkers with Individual Traumatic Brain Lesion Types in Mild Traumatic Brain Injury.Biomedicines · 2026Article
- Relevance of cerebral microbleeds with leaky blood brain barrier in traumatic brain injury and protective role of interferon-gamma: A cohort study.Cerebral circulation - cognition and behavior · 2026Article
- Association of Traumatic Brain Injury with Subsequent Psychiatric and Neurological Conditions: A Meta-Analysis.Journal of pharmacy & bioallied sciences · 2025Review
- Reduction of inflammatory biomarkers underlies extracellular vesicle mediated functional recovery in an aged monkey model of cortical injury.Frontiers in aging neuroscience · 2025Article
- Anti-inflammatory interleukin 1 receptor antagonist concentration in plasma correlates with blood-brain barrier integrity in the primary lesion area in traumatic brain injury patients.Brain, behavior, & immunity - health · 2023Article
- Multiplex Assessment of Serum Chemokines CCL2, CCL5, CXCL1, CXCL10, and CXCL13 Following Traumatic Brain Injury.Inflammation · 2023Article
- Sex-stratified RNA-seq analysis reveals traumatic brain injury-induced transcriptional changes in the female hippocampus conducive to dementia.Frontiers in neurology · 2022Article
- Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Plasma Biomarker for Post-concussive Syndrome: A Pilot Study Using an Alternating Current Electro-Kinetic Platform.Frontiers in neurology · 2020Article
- Neuroimaging of traumatic brain injury in military personnel: An overview.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2019Review
- Testing a Multivariate Proteomic Panel for Traumatic Brain Injury Biomarker Discovery: A TRACK-TBI Pilot Study.Journal of neurotrauma · 2019Article
- A novel antagonist of p75NTR reduces peripheral expansion and CNS trafficking of pro-inflammatory monocytes and spares function after traumatic brain injury.Journal of neuroinflammation · 2016Article
- Diffusion Tensor Imaging of TBI: Potentials and Challenges.Topics in magnetic resonance imaging : TMRI · 2015Review
- Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist.Pharmacology research & perspectives · 2015Article
- Inflammatory reaction after traumatic brain injury: therapeutic potential of targeting cell-cell communication by chemokines.Trends in pharmacological sciences · 2015Review
- Can Genetic Analysis of Putative Blood Alzheimer's Disease Biomarkers Lead to Identification of Susceptibility Loci?PloS one · 2015Article
- Adipokines: a link between obesity and dementia?The Lancet. Neurology · 2014Review
- The Potential Role of Chemokines in Alzheimer's Disease Pathogenesis.American journal of Alzheimer's disease and other dementias · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
We explored whether changes in the expression profile of peripheral blood plasma proteins may provide a clinical, readily accessible "window" into the brain, reflecting molecular alterations following traumatic brain injury (TBI) that might contribute to TBI complications. We recruited fourteen TBI and ten control civilian participants for the study, and also analyzed banked plasma specimens from 20 veterans with TBI and 20 control cases. Using antibody arrays and ELISA assays, we explored differentially-regulated protein species in the plasma of TBI compared to healthy controls from the two independent cohorts. We found three protein biomarker species, monocyte chemotactic protein-1 (MCP-1), insulin-like growth factor-binding protein-3, and epidermal growth factor receptor, that are differentially regulated in plasma specimens of the TBI cases. A three-biomarker panel using all three proteins provides the best potential criterion for separating TBI and control cases. Plasma MCP-1 contents are correlated with the severity of TBI and the index of compromised axonal fiber integrity in the frontal cortex. Based on these findings, we evaluated postmortem brain specimens from 7 mild cognitive impairment (MCI) and 7 neurologically normal cases. We found elevated MCP-1 expression in the frontal cortex of MCI cases that are at high risk for developing Alzheimer's disease. Our findings suggest that additional application of the three-biomarker panel to current diagnostic criteria may lead to improved TBI detection and more sensitive outcome measures for clinical trials. Induction of MCP-1 in response to TBI might be a potential predisposing factor that may increase the risk for development of Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.